Our Pricing

Understanding Retatrutide UK Availability and Licensed Alternatives

If you're searching for retatrutide UK options, it's important to understand that retatrutide is currently in clinical trials and not yet licensed by the MHRA for prescription use in the United Kingdom. However, proven alternatives with similar mechanisms—including tirzepatide (Mounjaro) and semaglutide (Wegovy)—are available through UK-registered pharmacies like Cured Pharmacy, offering significant weight loss outcomes backed by extensive clinical evidence.

What Is Retatrutide and Why Isn't It Available in the UK Yet?

Retatrutide is an investigational triple agonist peptide that activates GIP, GLP-1, and glucagon receptors simultaneously [1]. This three-pathway approach represents the next generation of metabolic therapies, building on the success of dual agonists like tirzepatide. In Phase 2 trials, participants achieved average weight reductions of up to 24.2% over 48 weeks, making it one of the most promising obesity treatments in development [1].

Currently, retatrutide UK availability is limited to clinical trial participation, as it has not yet received MHRA licensing for general prescription use. The medication is undergoing Phase 3 trials globally, with regulatory approval anticipated in 2025 or beyond. Until then, UK patients seeking advanced weight loss peptides can access licensed alternatives that work through similar biological pathways [2].

Licensed Retatrutide UK Alternatives: Mounjaro and Wegovy

While awaiting retatrutide UK approval, two MHRA-licensed medications offer comparable mechanisms and proven efficacy. Mounjaro (tirzepatide) is the UK's only dual GIP/GLP-1 receptor agonist, activating two of the three pathways that retatrutide targets [3]. In the SURPASS-2 trial, patients achieved an average 22.5% body weight reduction over 72 weeks—results that rival early retatrutide data [3].

Wegovy (semaglutide) works through selective GLP-1 receptor activation and demonstrated average weight loss of 14.9% in the STEP-1 trial [4]. Both treatments are administered as once-weekly subcutaneous injections and require clinical assessment by a UK prescriber before dispensing. At Cured Pharmacy, Mounjaro starts from £135.00 following a free online consultation with our UK-registered clinical team.

How These Alternatives Compare to Retatrutide

The key difference lies in receptor activation: retatrutide targets three pathways (GIP, GLP-1, glucagon), tirzepatide targets two (GIP, GLP-1), and semaglutide targets one (GLP-1). More pathways generally correlate with greater metabolic effects, but licensed dual and single agonists already deliver clinically significant outcomes. Your UK prescriber will recommend the most appropriate treatment based on your medical history, weight loss goals, and contraindications.

Retatrutide UK Clinical Trials: What the Evidence Shows

The Phase 2 trial published in The New England Journal of Medicine enrolled 338 adults with obesity across multiple international sites [1]. Participants receiving the highest retatrutide dose (12 mg weekly) lost an average of 24.2% of their baseline body weight over 48 weeks, compared to 2.1% in the placebo group. Importantly, 91% of participants in the highest-dose group achieved at least 5% weight loss, and 75% achieved at least 15% weight loss [1].

Common side effects mirrored those of other incretin-based therapies: nausea (60-70% of participants), diarrhoea, vomiting, and constipation, predominantly mild to moderate in severity [1]. Serious adverse events were rare and comparable across groups. These safety profiles informed the ongoing Phase 3 programme, which will determine whether retatrutide UK licensing proceeds.

Why Choose Cured Pharmacy for Weight Loss Treatments

As a GPhC-registered online pharmacy (registration number 9012511), Cured Pharmacy dispenses only genuine UK-licensed medications under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073). Every prescription treatment—including Mounjaro, Wegovy, and Saxenda—requires clinical assessment by a UK-registered prescriber, ensuring safe, personalised care that meets MHRA standards.

We offer transparent upfront pricing with no hidden consultation fees, 100% discreet packaging, and next-day delivery across the UK. Our online assessment takes under three minutes to complete, and you'll receive a clinical decision within hours. If approved, your medication is dispensed from our UK pharmacy and delivered directly to your door.

Our Weight Loss Treatment Range

Beyond injectable GLP-1 therapies, we stock oral weight loss aids including Orlistat (from £135.00), Xenical, and Alli capsules. These lipase inhibitors work by reducing dietary fat absorption and are suitable for patients who prefer tablet-based treatments. Your prescriber will discuss all licensed options during your consultation to identify the most effective approach for your individual circumstances.

How to Start Your Weight Loss Journey at Cured Pharmacy

Begin by completing our free online consultation, which gathers essential medical history including current medications, allergies, cardiovascular health, and previous weight loss attempts. A UK-registered prescriber reviews your assessment within hours and determines whether injectable or oral treatments are clinically appropriate. If Mounjaro or Wegovy is prescribed, you'll receive dosing instructions, injection technique guidance, and information on managing potential side effects.

Treatment typically starts at the lowest maintenance dose to minimise gastrointestinal symptoms, with gradual titration over 16-20 weeks as tolerated. Regular follow-up assessments monitor your progress, adjust dosing, and ensure ongoing suitability. Most patients begin noticing appetite reduction within the first week, with measurable weight loss evident by week four [3][4].

Retatrutide UK: Future Availability and What to Expect

Phase 3 trials for retatrutide are currently recruiting participants worldwide, with results expected by late 2025. If these trials replicate Phase 2 efficacy and safety outcomes, the manufacturer will submit regulatory applications to the MHRA, FDA, and EMA. UK licensing timelines typically extend 12-18 months beyond application submission, meaning widespread retatrutide UK availability may not occur until 2026 or 2027 [2].

Until then, patients seeking the most advanced licensed weight loss therapies can access tirzepatide through Cured Pharmacy. As a dual agonist, Mounjaro represents the current pinnacle of incretin-based treatment in the UK, offering superior outcomes to single-pathway medications while maintaining an acceptable safety profile. Our clinical team stays updated on emerging therapies and will offer retatrutide as soon as MHRA licensing is granted.

Staying Informed About New Treatments

We recommend subscribing to updates from Cured Pharmacy to receive notifications when retatrutide or other novel weight loss medications receive UK approval. In the meantime, our pharmacists are available at (+44) 116 4646009 to discuss current treatment options, answer questions about clinical trials, and provide evidence-based guidance on achieving sustainable weight loss with licensed therapies.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Medicines and Healthcare products Regulatory Agency. (2024). Clinical Trials Guidance: Obesity Treatments. GOV.UK. https://www.gov.uk/guidance/clinical-trials-for-medicines
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Retatrutide is not currently licensed by the MHRA for use in the UK.